Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALVR

AlloVir Inc

Mar 18 • 04:00PM ET

9.81

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRNA BMY VRTX REGN INCY BNTX SRPT NBIX NTLA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.73	Insider Own	9.29%	Shs Outstand	5.04M	Perf Week	3.37%
Market Cap	49.48M	Forward P/E	-	EPS next Y	0.00	Insider Trans	-10.27%	Shs Float	0.87M	Perf Month	-0.91%
Income	-	PEG	-	EPS next Q	-	Inst Own	13.66%	Short Float	6.75%	Perf Quarter	-7.28%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	2.63	Perf Half Y	-43.30%
Book/sh	22.60	P/B	0.43	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf Year	-41.31%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	7.96 - 24.15	Perf YTD	1.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-59.38%	Beta	0.58
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	23.24%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	72.12%	Oper. Margin	-	RSI (14)	50.87	Volatility	6.21% 5.77%
Employees	6	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.00	Prev Close	9.81
Sales Surprise	-	EPS Surprise	-66.26%	Sales Q/Q	-	Earnings	-	Avg Volume	22.41K	Price	9.81
SMA20	0.77%	SMA50	0.30%	SMA200	-33.56%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-26-23	Downgrade	BofA Securities	Buy → Underperform	$17 → $1
Dec-22-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-22-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-22-23	Downgrade	JP Morgan	Overweight → Underweight
Aug-18-23	Initiated	BofA Securities	Buy	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$48
Aug-24-20	Initiated	SVB Leerink	Outperform	$41
Aug-24-20	Initiated	Morgan Stanley	Overweight	$49
Aug-24-20	Initiated	JP Morgan	Overweight	$50

Mar-12-25 04:01PM	Kalaris and AlloVir Announce Stockholder Approval of Merger (GlobeNewswire) -5.69%
Nov-11-24 10:44AM	AlloVir and Kalaris enter merger to advance retinal disease therapies (Pharmaceutical Technology) +19.39%
Nov-08-24 07:04AM	Kalaris to go public via reverse merger with AlloVir (BioPharma Dive) -36.93%
06:00AM	AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina (GlobeNewswire)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in AlloVir Inc (GuruFocus.com)
02:52PM	Loading…
Aug-09-24 02:52PM	ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024 (InvestorPlace)
May-14-24 08:53AM	ALVR Stock Earnings: AlloVir Misses EPS for Q1 2024 (InvestorPlace)
Mar-18-24 03:53PM	ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023 (InvestorPlace) -6.03%
Mar-13-24 11:53AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights ALVR (GlobeNewswire)
10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir (PR Newswire)
Mar-12-24 05:50AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR (PR Newswire)
Mar-06-24 06:17PM	ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire)
Mar-04-24 05:37PM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-28-24 01:06AM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
12:27PM	Loading…
Feb-26-24 12:27PM	AlloVir, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALVR (GlobeNewswire)
Feb-23-24 10:30AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-29-24 09:40AM	Are Medical Stocks Lagging AlloVir (ALVR) This Year? (Zacks)
Jan-24-24 09:45AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-12-24 09:35AM	Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR) (Zacks) +5.30%
Jan-05-24 11:03AM	AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts (InvestorPlace)
08:37AM	Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce (FierceBiotech.com)
Dec-26-23 10:04AM	Karuna downgraded, Arm target raised: Wall Street's top analyst calls (The Fly)
Dec-22-23 09:31AM	Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls (The Fly) -67.15%
08:30AM	AlloVir's shares plunge 64% as cell therapy biotech weighs options in wake of triple phase 3 disaster (FierceBiotech.com)
07:10AM	AlloVir scraps late-stage studies testing antiviral cell therapy (Reuters)
07:00AM	AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-16-23 07:00AM	AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-02-23 10:04AM	AlloVir Inc (ALVR) Reports Q3 2023 Financial Results (GuruFocus.com) +13.64%
07:00AM	Loading…
07:00AM	AlloVir Reports Third Quarter 2023 Financial Results (Business Wire)
Sep-21-23 02:44PM	Why AlloVir Stock Dropped Today (Motley Fool)
Sep-14-23 09:59AM	These 2 Strong Buy Penny Stocks Could Soar to $17 (Or Higher), Say Analysts (TipRanks) +9.72%
Aug-28-23 07:00AM	AlloVir to Present at Upcoming Investor Conferences (Business Wire) +7.00%
Aug-03-23 07:00AM	AlloVir Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) +7.55%
Jul-12-23 03:12AM	Gilead Just Bought $30 Million More of 2 Biotech Stocks (Barrons.com) +6.76%
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jul-03-23 03:59AM	5 hot insider trades & hedge fund hits: Buffett picks up more Occidental shares (Investing.com)
Jun-27-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why (Zacks)
Jun-23-23 01:56PM	Why Shares of AlloVir Plummeted This Week (Motley Fool)
Jun-21-23 09:20PM	AlloVir Announces Pricing of Public Offering of Common Stock (Business Wire) -35.70%
04:18PM	AlloVir Announces Proposed Public Offering of Common Stock (Business Wire)
Jun-09-23 11:04AM	Why Shares of AlloVir Jumped This Week (Motley Fool) -7.83%
Jun-05-23 07:00AM	AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023) (Business Wire) +12.63%
May-16-23 07:00AM	AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer (Business Wire)
May-04-23 07:00AM	AlloVir Reports First Quarter 2023 Financial Results (Business Wire) +10.36%
May-01-23 07:00AM	AlloVir to Present at the BofA Securities 2023 Health Care Conference (Business Wire) +8.14%
Apr-26-23 05:12PM	AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections (Benzinga)
07:00AM	AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023 (Business Wire)
Mar-30-23 11:12AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.) -5.67%
Feb-23-23 04:15PM	AlloVir Appoints Derek Adams, Ph.D., to Board of Directors (Business Wire) +7.14%
Feb-15-23 10:05AM	AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall (Benzinga) -5.17%
07:07AM	AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook (Business Wire)
07:00AM	AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia (Business Wire)
Feb-10-23 09:55AM	Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks)
Feb-07-23 10:17AM	Sage and Biogen's NDA for Depression Drug Gets Priority Review (Zacks)
Feb-01-23 07:00AM	AlloVir to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-25-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% (Zacks)
09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Jan-09-23 07:00AM	AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 (Business Wire)
Jan-03-23 07:00AM	AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-10-22 05:15PM	AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition (Business Wire)
Nov-15-22 07:00AM	AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference (Business Wire) -5.21%
Nov-03-22 09:07AM	Final Data from AlloVirs Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting (Business Wire)
07:00AM	AlloVir Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-21-22 08:30AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-06-22 09:55AM	Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High? (Zacks) -5.10%
Aug-31-22 07:00AM	AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) +19.97%
Aug-19-22 09:55AM	Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect? (Zacks)
Aug-04-22 07:00AM	AlloVir Reports Second Quarter 2022 Financial Results (Business Wire) +12.22%
Aug-03-22 09:55AM	Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks) +5.06%
Aug-01-22 08:09AM	Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares? (Simply Wall St.)
Jul-27-22 07:00AM	AlloVir Announces $126.6 Million Registered Direct Offering (Business Wire) +11.93%
Jun-07-22 12:07PM	AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients (Benzinga)
08:30AM	AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients (Business Wire)
May-05-22 07:00AM	AlloVir Reports First Quarter 2022 Financial Results (Business Wire)
Apr-21-22 11:35AM	AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel (Zacks) -13.28%
Apr-20-22 07:00AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +15.53%
Apr-04-22 07:40PM	Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation (Simply Wall St.) -6.37%
Mar-31-22 07:00AM	AlloVir Appoints Shawn Tomasello to Its Board of Directors (Business Wire) -6.77%
Mar-23-22 09:56AM	AlloVir (ALVR) Begins Study to Prevent Six Viral Infections (Zacks)
Mar-22-22 07:00AM	AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +7.25%
Feb-11-22 07:00AM	AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-10-22 07:00AM	AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook (Business Wire)
Jan-05-22 07:30AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation (Business Wire)
Jan-03-22 04:05PM	AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.07%
Dec-16-21 04:05PM	AlloVir Announces Departure of Chief Medical Officer Augustin Melian (Business Wire) -6.32%
Dec-11-21 01:00PM	AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting (Business Wire)
Nov-17-21 11:57AM	Allovir Insider Sold Over $465K In Company Stock (Benzinga)
Nov-15-21 07:00AM	AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (Business Wire)
Nov-10-21 11:48AM	Allovir Insider Trades $300K In Company Stock (Benzinga)
Nov-05-21 07:00AM	AlloVir Reports Third Quarter 2021 Financial Results (Business Wire)
Oct-29-21 09:47AM	Morgan Stanley: These 2 Strong Buy Stocks Could Double From Here (TipRanks)
Oct-06-21 11:31AM	Notable Allovir Insider Makes $445K Sale (Benzinga)
Oct-05-21 06:48AM	Companies Like AlloVir (NASDAQ:ALVR) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-04-21 07:00AM	FDA Grants Orphan Drug Designation (ODD) to AlloVirs Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis (Business Wire) -12.20%
Sep-29-21 02:09PM	Hedge Funds Are Buying AlloVir, Inc. (ALVR) (Insider Monkey)
07:00AM	Data Presented at IDWeek 2021 Demonstrate that ALVR109, AlloVirs Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta (Business Wire)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sinha Vikas	See Remarks	Feb 21 '25	Sale	10.08	303	3,053	49,129	Feb 24 04:15 PM
Hagen Brett R	Chief Accounting Officer	Feb 21 '25	Sale	10.08	96	967	2,832	Feb 24 04:15 PM
Miller Edward	General Counsel	Feb 21 '25	Sale	10.08	106	1,068	6,517	Feb 24 04:15 PM
Sinha Vikas	Owner	Feb 21 '25	Proposed Sale	4.30	709	3,052		Feb 24 11:56 AM
Miller Edward	Officer	Feb 21 '25	Proposed Sale	3.70	289	1,068		Feb 24 11:55 AM
Hagen Brett R	Officer	Feb 21 '25	Proposed Sale	10.07	96	967		Feb 24 11:51 AM
Miller Edward	General Counsel	Jan 23 '25	Sale	9.50	52	494	6,623	Jan 27 04:16 PM
Hagen Brett R	Chief Accounting Officer	Jan 23 '25	Sale	9.51	36	342	2,928	Jan 27 04:15 PM
Sinha Vikas	See Remarks	Jan 23 '25	Sale	9.50	129	1,226	49,432	Jan 27 04:11 PM
Sinha Vikas	Owner	Jan 23 '25	Proposed Sale	9.55	129	1,232		Jan 24 03:03 PM
Miller Edward	Officer	Jan 23 '25	Proposed Sale	9.52	52	495		Jan 24 02:55 PM
Hagen Brett R	Officer	Jan 23 '25	Proposed Sale	9.47	36	341		Jan 24 02:51 PM
Miller Edward	General Counsel	Jan 10 '25	Sale	0.44	409	180	153,541	Jan 13 04:15 PM
Hagen Brett R	Chief Accounting Officer	Jan 10 '25	Sale	0.44	332	146	68,174	Jan 13 04:15 PM
Sinha Vikas	See Remarks	Jan 10 '25	Sale	0.44	979	431	1,139,915	Jan 13 04:15 PM
Miller Edward	Officer	Jan 10 '25	Proposed Sale	0.44	409	180		Jan 10 08:00 PM
Sinha Vikas	Owner	Jan 10 '25	Proposed Sale	0.44	979	431		Jan 10 08:00 PM
Hagen Brett R	Officer	Jan 10 '25	Proposed Sale	0.44	332	146		Jan 10 08:00 PM
Hagen Brett R	Chief Accounting Officer	Nov 19 '24	Sale	0.55	554	304	68,506	Nov 20 04:15 PM
Sinha Vikas	See Remarks	Nov 19 '24	Sale	0.55	3,186	1,748	1,140,894	Nov 20 04:15 PM
Miller Edward	General Counsel	Nov 19 '24	Sale	0.55	432	237	211,499	Nov 20 04:15 PM
Brainard Diana	Chief Executive Officer	Nov 19 '24	Sale	0.55	8,706	4,775	723,363	Nov 20 04:15 PM
Sinha Vikas	Owner	Nov 19 '24	Proposed Sale	0.54	3,186	1,735		Nov 19 08:00 PM
Miller Edward	Officer	Nov 19 '24	Proposed Sale	0.54	432	235		Nov 19 08:00 PM
Brainard Diana	Officer	Nov 19 '24	Proposed Sale	0.55	8,706	4,763		Nov 19 08:00 PM
Hagen Brett R	Officer	Nov 19 '24	Proposed Sale	0.55	554	302		Nov 19 08:00 PM
Brainard Diana	Chief Executive Officer	Nov 05 '24	Sale	0.86	10,609	9,176	732,069	Nov 06 04:15 PM
Miller Edward	General Counsel	Nov 05 '24	Sale	0.86	2,272	1,965	211,931	Nov 06 04:15 PM
Hagen Brett R	Chief Accounting Officer	Nov 05 '24	Sale	0.86	1,655	1,431	69,060	Nov 06 04:15 PM
Sinha Vikas	See Remarks	Nov 05 '24	Sale	0.86	5,136	4,442	1,144,080	Nov 06 04:15 PM
Brainard Diana	Officer	Nov 05 '24	Proposed Sale	0.86	10,609	9,176		Nov 05 08:00 PM
Miller Edward	Officer	Nov 05 '24	Proposed Sale	0.86	2,272	1,965		Nov 05 08:00 PM
Hagen Brett R	Officer	Nov 05 '24	Proposed Sale	0.86	1,655	1,431		Nov 05 08:00 PM
Sinha Vikas	Owner	Nov 05 '24	Proposed Sale	0.86	5,136	4,442		Nov 05 08:00 PM
Brainard Diana	Chief Executive Officer	Oct 21 '24	Sale	0.78	9,752	7,597	742,678	Oct 23 04:15 PM
Sinha Vikas	See Remarks	Oct 22 '24	Sale	0.77	1,882	1,445	1,149,216	Oct 23 04:15 PM
Sinha Vikas	See Remarks	Oct 21 '24	Sale	0.78	1,546	1,204	1,151,098	Oct 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Oct 22 '24	Sale	0.77	486	373	70,715	Oct 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Oct 21 '24	Sale	0.78	479	373	71,201	Oct 23 04:15 PM
Miller Edward	General Counsel	Oct 22 '24	Sale	0.77	766	588	214,203	Oct 23 04:15 PM
Miller Edward	General Counsel	Oct 21 '24	Sale	0.78	635	495	214,969	Oct 23 04:15 PM
Hagen Brett R	Officer	Oct 22 '24	Proposed Sale	0.77	486	373		Oct 22 08:00 PM
Miller Edward	Officer	Oct 22 '24	Proposed Sale	0.77	766	588		Oct 22 08:00 PM
Sinha Vikas	Owner	Oct 22 '24	Proposed Sale	0.77	1,882	1,445		Oct 22 08:00 PM
Sinha Vikas	Owner	Oct 21 '24	Proposed Sale	0.78	1,546	1,204		Oct 21 08:00 PM
Hagen Brett R	Officer	Oct 21 '24	Proposed Sale	0.78	479	373		Oct 21 08:00 PM
Brainard Diana	Officer	Oct 21 '24	Proposed Sale	0.78	9,752	7,596		Oct 21 08:00 PM
Miller Edward	Officer	Oct 21 '24	Proposed Sale	0.78	635	495		Oct 21 08:00 PM
Sinha Vikas	See Remarks	Oct 03 '24	Sale	0.81	940	766	1,152,644	Oct 04 04:15 PM
Miller Edward	General Counsel	Oct 03 '24	Sale	0.81	377	307	215,604	Oct 04 04:15 PM
Brainard Diana	Chief Executive Officer	Oct 03 '24	Sale	0.81	1,493	1,216	752,430	Oct 04 04:15 PM
Hagen Brett R	Chief Accounting Officer	Oct 03 '24	Sale	0.81	301	245	71,680	Oct 04 04:15 PM
Brainard Diana	Officer	Oct 03 '24	Proposed Sale	0.81	1,493	1,216		Oct 03 08:00 PM
Sinha Vikas	Owner	Oct 03 '24	Proposed Sale	0.81	940	766		Oct 03 08:00 PM
Miller Edward	Officer	Oct 03 '24	Proposed Sale	0.81	377	307		Oct 03 08:00 PM
Hagen Brett R	Officer	Oct 03 '24	Proposed Sale	0.81	301	245		Oct 03 08:00 PM
Brainard Diana	Chief Executive Officer	Aug 20 '24	Sale	0.74	5,390	3,996	753,923	Aug 22 04:15 PM
Brainard Diana	Officer	Aug 20 '24	Proposed Sale	0.74	5,390	3,996		Aug 21 11:14 AM
Miller Edward	General Counsel	Aug 19 '24	Sale	0.76	422	321	215,981	Aug 20 04:15 PM
Sinha Vikas	See Remarks	Aug 19 '24	Sale	0.76	3,159	2,399	1,153,584	Aug 20 04:15 PM
Hagen Brett R	Chief Accounting Officer	Aug 19 '24	Sale	0.76	544	413	71,981	Aug 20 04:15 PM
Brainard Diana	Chief Executive Officer	Aug 19 '24	Sale	0.76	3,091	2,348	759,313	Aug 20 04:15 PM
Sinha Vikas	Owner	Aug 19 '24	Proposed Sale	0.76	3,159	2,399		Aug 19 08:00 PM
Brainard Diana	Officer	Aug 19 '24	Proposed Sale	0.76	3,091	2,348		Aug 19 08:00 PM
Hagen Brett R	Officer	Aug 19 '24	Proposed Sale	0.76	544	413		Aug 19 08:00 PM
Miller Edward	Officer	Aug 19 '24	Proposed Sale	0.76	422	321		Aug 19 08:00 PM
Miller Edward	General Counsel	Aug 05 '24	Sale	0.73	2,323	1,707	216,403	Aug 07 04:15 PM
Brainard Diana	Chief Executive Officer	Aug 05 '24	Sale	0.73	10,847	7,970	762,404	Aug 07 04:15 PM
Sinha Vikas	See Remarks	Aug 05 '24	Sale	0.73	5,251	3,858	1,156,743	Aug 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	Aug 05 '24	Sale	0.73	1,692	1,243	72,525	Aug 07 04:15 PM
Brainard Diana	Officer	Aug 05 '24	Proposed Sale	0.73	10,847	7,970		Aug 06 08:00 PM
Sinha Vikas	Owner	Aug 05 '24	Proposed Sale	0.73	5,251	3,858		Aug 06 08:00 PM
Hagen Brett R	Officer	Aug 05 '24	Proposed Sale	0.73	1,692	1,243		Aug 06 08:00 PM
Miller Edward	Officer	Aug 05 '24	Proposed Sale	0.73	2,323	1,707		Aug 06 08:00 PM
Hagen Brett R	Chief Accounting Officer	Jul 19 '24	Sale	0.75	479	359	74,698	Jul 23 04:28 PM
Hagen Brett R	Chief Accounting Officer	Jul 22 '24	Sale	0.74	481	356	74,217	Jul 23 04:28 PM
Brainard Diana	Chief Executive Officer	Jul 19 '24	Sale	0.75	9,731	7,299	773,251	Jul 23 04:28 PM
Sinha Vikas	See Remarks	Jul 22 '24	Sale	0.74	1,858	1,373	1,161,994	Jul 23 04:27 PM
Sinha Vikas	See Remarks	Jul 19 '24	Sale	0.75	1,542	1,157	1,163,852	Jul 23 04:27 PM
Miller Edward	General Counsel	Jul 22 '24	Sale	0.74	757	560	218,726	Jul 23 04:25 PM
Miller Edward	General Counsel	Jul 19 '24	Sale	0.75	634	476	219,483	Jul 23 04:25 PM
Miller Edward	General Counsel	Jul 02 '24	Sale	0.72	379	273	220,117	Jul 03 04:14 PM
Sinha Vikas	See Remarks	Jul 02 '24	Sale	0.72	939	676	1,165,394	Jul 03 04:14 PM
Hagen Brett R	Chief Accounting Officer	Jul 02 '24	Sale	0.72	304	219	75,177	Jul 03 04:12 PM
Brainard Diana	Chief Executive Officer	Jul 02 '24	Sale	0.72	1,489	1,072	782,982	Jul 03 04:11 PM
Brainard Diana	Chief Executive Officer	May 21 '24	Sale	0.79	5,149	4,080	784,471	May 23 05:24 PM
Hagen Brett R	Chief Accounting Officer	May 17 '24	Sale	0.75	541	405	75,481	May 21 04:35 PM
Brainard Diana	Chief Executive Officer	May 17 '24	Sale	0.75	3,075	2,304	789,620	May 21 04:35 PM
Sinha Vikas	See Remarks	May 17 '24	Sale	0.75	3,143	2,355	1,129,996	May 21 04:33 PM
Miller Edward	General Counsel	May 17 '24	Sale	0.75	420	315	220,496	May 21 04:33 PM
Brainard Diana	Chief Executive Officer	May 03 '24	Sale	0.80	10,240	8,151	792,695	May 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	May 03 '24	Sale	0.80	1,597	1,271	76,022	May 07 04:15 PM
Sinha Vikas	See Remarks	May 03 '24	Sale	0.80	4,957	3,946	1,133,139	May 07 04:15 PM
Miller Edward	General Counsel	May 03 '24	Sale	0.80	2,311	1,840	220,916	May 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 22 '24	Sale	0.75	480	360	77,619	Apr 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 19 '24	Sale	0.75	473	355	78,099	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 22 '24	Sale	0.75	757	568	223,227	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 19 '24	Sale	0.75	626	470	223,984	Apr 23 04:15 PM
Brainard Diana	Chief Executive Officer	Apr 19 '24	Sale	0.75	9,601	7,207	802,935	Apr 23 04:15 PM
Sinha Vikas	See Remarks	Apr 22 '24	Sale	0.75	1,857	1,393	1,138,096	Apr 23 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALVR

AlloVir Inc

Upgrade your FINVIZ experience